The current work aimed to study the antitumour activity of a phenolic extract of the edible mushroom Leccinum vulpinum Watling, rich essentially in hydroxybenzoic acids.
Introduction
It is recognized worldwide that mushrooms are an excellent food both from a nutritional and bioactive point of view (Cheung, 2010; Roupas et al., 2012; Wasser, 2011) . Indeed, according to the literature, in addition to their nutritional value, mushrooms have also been recognized for their therapeutic value (Öztürk et al., 2015) .
Among these health benefits, the antitumor potential of different mushroom species and/or their components is well recognized by the scientific community . Actually, there is some evidence (from case-control studies in humans subjected to controlled diets) of an inverse relationship between the consumption of mushrooms and breast cancer risk (Hong et al., 2008; Roupas et al., 2012; Shin et al., 2010; Zhang et al., 2009) . Moreover, there are some studies attesting the beneficial effects of some mushroom extracts in cancer patients. An Agaricus blazei extract has been reported to have beneficial effects in gynecological cancer patients undergoing chemotherapy, maintaining their immune activities and improving their quality of life (Ahn et al., 2004) . Furthermore, the efficacy of PSK (Polysaccharide-K, obtained from Trametes versicolor) as an adjuvant immunotherapy agent after surgery has been described, in patients with colorectal cancer by increasing the patients survival and reducing the recurrence risk (Ito et al., 2004; Mitomi et al., 1992; Ohwada et al., 2004; Torisu et al., 1990 ), as well as in patients with gastric cancer (Nakazato et al., 1994; Tsujitani et al., 1992) . In addition, dietary supplementation with an extract from Agaricus sylvaticus showed to be beneficial in postsurgical patients with colorectal cancer (Fortes et al., 2009 ).
The phenolic compounds are amongst the compounds with higher bioactivity (Öztürk et al., 2015) . Indeed, the phenolic compounds, present in both wild and cultivated mushrooms, have been recognized as bioactive compounds which may be extracted for the purpose of being used as functional constituents (Cheung, 2010; Palacios et al., 4 2011; Patel and Goyal, 2012; Reis et al., 2012; Vaz et al., 2012a) . Likewise, mushrooms might be used directly in diet, promoting health benefits and taking advantage of the additive and synergistic effects of their bioactive compounds (Ferreira et al., 2009 ).
There are very few studies on the Leccinum vulpinum Watling mushroom species. To our knowledge, such studies have only outlined its morphological description (Ellis and Ellis, 1990) , as well as some of its ecological (Iwański and Rudawska, 2007; Saxén and Ilus, 2008; Vaaramaa et al., 2009 ) and enzymatic characteristics (Chen et al., 2001 and .
Taking into account the facts aforementioned regarding the potential of mushrooms and their components, and since there are no studies on L. vulpinum bioactivity, in the present work the antitumour potential of a phenolic extract obtained from this species was evaluated. The extract was initially chemically characterized by chromatographic techniques so as to measure their phenolic acids content. Afterwards, the extract was tested against a panel of four human tumour cell lines, in order to perform a first assessment of its effect on the growth of human tumour cell lines. Moreover, some functional assays were performed in order to further evaluate the effects of the phenolic extract on the MCF-7 cells (i.e., cell proliferation, cell cycle profile and apoptosis).
Additionally, the effects of the extract as an inducer of DNA damage were also evaluated, given that DNA damage is a mechanism of action of several cytotoxic drugs, which may lead to cell cycle arrest (inhibiting proliferation) and apoptosis.
Material and methods

Mushroom species and samples preparation
Leccinum vulpinum Watling wild samples were collected in Bragança (Northeast of Portugal) in the autumn of 2012. Authentications were undertaken at the Polytechnic Institute of Bragança and voucher specimens were deposited at the herbarium of the School of Agriculture of the Polytechnic Institute of Bragança, Portugal.
All samples were lyophilised (FreeZone 4.5 model 7750031, Labconco, Kansas City, MO, USA), reduced to a fine dried powder (20 mesh), mixed and stored in a desiccator, protected from light.
Extraction procedure and chromatographic characterization of the extract
The extraction procedure and chromatographic characterization were performed according to the procedure described by other authors (Reis et al., 2012) . Briefly, approximately 1.5 g of lyophilized sample was extracted with methanol:water (80:20, v/v; 30 mL) at -20°C. The analysis of phenolic compounds contained in the sample was performed by ultra fast liquid chromatography (UFLC, Shimadzu 20A series; UFLC, Shimadzu Coperation, Kyoto, Japan) and the detection was carried out in a photodiode array detector (PDA), using 280 nm as the preferred wavelength. The phenolic compounds present in the studied extract were characterised according to their UV and retention times compared with commercial standards. The quantitative analysis of the compounds, was based on the calibration curve obtained by the injecting of known concentrations of each standard compound: cinnamic acid, gallic acid, phydroxybenzoic acid and protocatechuic acid. The results were expressed in µg per g of extract.
For the biological assays, the residue extracts were re-dissolved in distillated water (8 mg/mL).
Screening for the cell growth inhibitory activity in human tumour cell lines and cytotoxicity evaluation
6
The screening for tumour cell growth inhibitory activity was carried out using the sulforhodamine B (SRB) assay, a procedure adopted by the NCI's in vitro anticancer drug screening (Neves et al., 2011; Vichai and Kirtikara, 2006 (Azevedo et al., 2013; Vaz et al., 2010) . Cells were then incubated for 48 h with five serial dilutions of the extract, ranging from 12.5 µg/mL to 400 µg/mL to 2 x 10 -7 M) and etoposide (tested concentrations from 9 x 10 -7 to 14 x 10 -6 M) were used as positive controls. The H 2 O (vehicle used to dissolve the extracts) concentrations used (5%) were also tested (control treatments). Another control was included, consisting in cells growing in complete culture medium only (blank treatment).
For the cytotoxicity evaluation, the human breast non-malignant cell line MCF-10A was used. The cell line was obtained from ATCC (American Type Culture Collection, Manassas, VA). MCF-10A cells were cultured in Dulbecco's modified Eagle's medium (DMEM): F12, supplemented with 5% heat inactivated horse serum, 10 µg/ml insulin, 0.5 µg/ml hydrocortisone, 20 ng/ml epidermal growth factor (EGF), and 100 ng/ml cholera toxin (Sigma-Aldrich, St Louis, MO). The cells were routinely cultured in a humidified atmosphere with 5% CO 2 and at 37ºC and used in experiments when reached 70% -80% confluence. Cells were plated in 96-well plates at the same density as MCF-7 (5.0 × 10 3 cells/well) and allowed to adhere for 24 h. Cells were treated for 48 h with the different diluted sample solutions and a similar procedure described previously for the SRB assay was followed. The results were also expressed as GI 50
values and doxorubicin was used as a positive control. 
Cell biological assays used to
Cell proliferation analysis
Cell proliferation was analysed with the BrdU assay, according to the protocol previously described by Palmeira et al. (2010) . Briefly, cells were treated for 48 h 
Cell cycle distribution analysis
Following the 48 h treatments, cells were harvested and fixed with ice-cold 70% ethanol and stored at 4°C for at least 12 h, until further analysis. Cells were re-suspended in PBS containing RNase A (0.1 mg/mL) and propidium iodide (5 µg/mL). Cellular DNA content was analysed by flow cytometry (BD Accuri™ C6 Flow cytometer, USA) and the percentage of cells in the G1, S and G2/M phases of the cell cycle (as well as the percentage of cells in the sub-G1 peak) was determined using the FlowJo 7.6.5 software (Tree Star, Inc., Ashland, OR, USA) after cell debris and aggregates exclusion and plotting at least 15 000 events per sample (Vasconcelos et al., 2000) .
Apoptosis analysis
Induced apoptosis was assayed by Flow cytometry using the Human Annexin V-FITC/PI apoptosis kit (Bender MedSystems, Vienna, Austria), according to the manufacturer's instructions, as previously described (Queiroz et al., 2013) . Flow cytometry was carried out using the flow cytometer mentioned above and plotting at least 15 000 events per sample. Data were analysed using the BD Accuri C6 Software (version 1.0.264.21). Amersham Hyperfilm ECL and the Kodak GBX developer and fixer were used for signal detection, as previously described (Lima et al., 2006) .
Protein expression analysis
Analysis of DNA Damage
DNA damage was analysed with the Alkaline Comet Assay 24 h after treatment with the phenolic extract or control treatments. This incubation period was selected (instead of 48 h) to evaluate the first DNA degradation stages that occurred, prior to cellular apoptosis. Hydrogen peroxide was used as positive control (1 mM) and it was added 10 min before cells harvesting. Harvested cells were stored in 10% DMSO in FBS at -80ºC, following a procedure previously described by other authors (Seca et al., 2014) .
Briefly, after thawing, cells were washed with PBS, resuspended in 0.6% low melting point agarose and quickly poured onto slides, precoated with 1% agarose in water, with the aid of a coverslip. Slides were kept 10 min on ice. After removing the coverslip, cells were lysed with ice-cold lysis buffer (100mM Na 2 EDTA, 2.5M NaCl, 10mM TrisHCl, pH 10.0, 1% Triton X-100) for 2 h, in the dark, at 4 ºC, and then washed twice in ice-cold distilled water for 10 min. Slides were placed on an electrophoresis tank filled with electrophoresis buffer (10 M NaOH; 200mM Na 2 EDTA) and incubated for 20 min to let DNA to unwind. Electrophoresis was carried out for 20 min at 23 V, 300 mA.
After this period, slides were flooded with neutralisation buffer (0.4 M Tris, pH 7.5) for 20 min and then rinsed in ice-cold water for 10 min before being allowed to dry at room temperature overnight. Slides were rehydrated with distilled water (for 30 min), covered with 2.5 µg/mL of propidium iodide solution and incubated for 20 min at room temperature in the dark. Propidium iodide was rinsed with distilled water for 30 min and slides dried at 37ºC. Comets were visualized using the fluorescent microscope mentioned above and representative photographs were taken. The analysis was made using the 'Comet Assay IV v4.3' imaging system (Perceptive Instruments). A minimum of 100 cells per condition were analysed.
Statistical analysis
All experimental data is presented as mean ± standard deviation (SD) or standard error (SE), from at least three independent experiments (most of them performed in duplicate). Statistical analysis was carried out using an unpaired student's t-test. All analyses were performed comparing cells treated with the phenolic extract with Blank cells (cells incubated with medium only). *Indicates p < 0.05. vulpinum extracts. Based on the statement that mushrooms and their components have numerous positive health benefits, in the present work it was intend to discover new bioactive extracts from unstudied species. For that, we tested a phenolic extract from L. vulpinum for its antitumour properties, initiating the study with its chemical characterization. Fig. 1 . Phenolic acids individual profile of the studied phenolic extract from Leccinum vulpinum Watling. 1-gallic acid; 2-protocatechuic acid; 3-p-hydroxybenzoic acid; 4-cinnamic acid.
Results and discussion
Chromatographic characterization of the phenolic extract from
Table 1
Phenolic acids and cinnamic acid present in the phenolic extract from Leccinum vulpinum Watling (µg/g extract)
As previously referred, mushroom phenolic compounds have been reported to contribute to the bioactivity of several species. The studied phenolic extract exhibited the presence of gallic acid (18.4 µg/g extract), protocatechuic acid (77 µg/g extract) and p-hydroxybenzoic acid (20 µg/g extract; Fig. 1 ; Table 1 ). Accordingly, the main molecular group of phenolic compounds found in this mushroom specie was the hydroxybenzoic acids one, which comprises, besides p-hydroxybenzoic acid, gallic and protocatechuic acids. Gallic acid has been referred as having anticancer properties in several models such as prostate carcinoma DU145 and 22Rv1 cells (Kaur et al., 2009 ), non-small-cell lung cancer NCI-H460 cells (Ji et al., 2009) , HeLa cervical cancer cells (You et al., 2010) , leukaemia K562 cells (Reddy et al., 2012) , and glioblastoma U87 and U251n cells, and having been pointed out as a valuable candidate for treatment of brain tumour (Lu et al., 2010) . Protocatechuic acid has also been referred as having antitumour potential, namely as an inducer of cell death in HepG2 hepatocellular carcinoma cells (Yip et al., 2006) , human breast cancer MCF-7 cells, lung cancer A549 cells, cervix HeLa cells, and prostate cancer LNCaP cells (Yin et al., 2009 ). Even though there are not many publications regarding the antitumour potential of p-hydroxybenzoic acid, it has been reported as a component of some phenolic extracts with cytotoxicity/antitumour activity. This is the case of fermentation products of the medicinal plant Houttuynia cordata (Senawong et al., 2014) or honey samples (Spilioti et al., 2014) . In some studies with mushrooms, the synergistic effects concerning the cytotoxicity of phenolic acids in human tumour cell lines have been reported, even when the isolated compounds (e.g. p-hydroxybenzoic acid) do not have such activity on their own (Heleno et al., 2014; Vaz et al., 2012a) . Thus, phydroxybenzoic acid may exert antitumour effects when associated with other compounds, since there is also evidence that their own derivatives have antiproliferative and proapoptotic activities (Seidel et al., 2014) .
Cinnamic acid was also found in the studied mushroom extract (38.0 µg/g extract).
Cinnamic acid has been also reported as having anticancer properties. This natural compound inhibits the proliferation and modulates brush border membrane enzyme activities in colorectal adenocarcinoma Caco-2 cell line (Ekmekcioglu et al., 1998) .
Considering these aspects, the presence of the mentioned phenolic compounds (and of the related compound cinnamic acid) in L. vulpinum phenolic extract is possibly responsible for its bioactive properties.
Cell growth inhibitory activity of the phenolic extract from L. vulpinum in human tumour cell lines and cytotoxicity in MCF-10A cells
There are some reports on tumour cell growth inhibitory activity of some phenolic extracts/compounds from other species of mushrooms (Heleno et al., 2014; Patel and Goyal, 2012; Vaz et al., 2012a) . Nevertheless, to our knowledge such activity has never been previously investigated in the phenolic extracts of the L. vulpinum species.
Therefore, in this work its effect on tumour cell growth inhibition was evaluated using a panel of four human tumour cell lines (MCF-7, NCI-H460, HCT-15 and AGS). 53 ± 6 µg/mL 116 ± 8 µg/mL 135 ± 2 µg/mL 99 ± 11 µg/mL 297 ± 9 µg/mL Positive controls Etoposide 6.8 ± 0.6 µM The extract inhibited the cell growth of all the cell lines tested (Table 2 ) and the lowest GI 50 concentrations were obtained in HCT-15 and MCF-7 cell lines. Positive controls were used for all the tested cells. Doxorubicin and etoposide are both used in cancer chemotherapy (Varaprasad et al., 2010; Chabner and Longo, 2011) . Doxorubicin was selected as the main positive control; however, since the HCT-15 cell line was not very sensitive to this drug, presenting GI 50 values higher than the maximum tested (200 nM), etoposide was used as a positive control in this case.
It was decided to continue the studies in the MCF-7 cells since, as aforementioned, there is evidence for an inverse relationship between mushroom consumption and breast cancer risk.
In order to assess the safety of using this phenolic extract, its cytotoxicity was tested in the human breast non-malignant cell line, MCF-10A. Although the phenolic extract of much higher than those obtained in the breast tumour (MCF-7) cells (three times higher; Table 2 ). Therefore, the phenolic extract from L. vulpinum inhibited the growth of different human tumour cell lines, but was less toxic to the non-tumourigenic breast cancer cell line.
Effects of the phenolic extract of L. vulpinum on the human MCF-7 breast cancer cell line
L. vulpinum phenolic extract decreased proliferation of MCF-7 cells
There are some reports regarding the effect of mushroom extracts of other mushroom species on the proliferation of human tumour cell lines (dos 2014; Yu et al., 2014) . In order to verify if the L. vulpinum phenolic extract interfered with the proliferation of MCF-7 cells, the levels of BrdU incorporation were analysed following 48 h treatment. As shown in Fig. 2 , the studied extract reduced cellular proliferation. Nevertheless, the effect on cell proliferation was only considered statistically significant with the GI 75 concentration (159 µg/mL). The fact the GI 50 concentration of the extract did not cause a statistically significant reduction on cell proliferation, may be due to an effect on cellular apoptosis at that concentration (see section 3.3.3. below) rather than an effect on cell cycle (proliferation). Indeed, it is possible that, although there is a decrease in the cell number following treatment with the GI 50 concentration, the % of cells in the S-phase (which incorporate BrdU) is not altered. 
L. vulpinum phenolic extract did not alter cell cycle distribution of MCF-7 cells
Once differences in cellular proliferation were observed, the next step was to determine whether the extract caused cell cycle arrest. As previously referred, MCF-7 cells were treated with the GI 50 and GI 75 concentrations of the phenolic extract under study. From the analysis of the results obtained, no significant differences were observed in the different phases of the cell cycle (Fig. 3) . Having decreased cellular proliferation, we would expect that the extract would cause cell cycle arrest. These discrepancies may also be justified by the fact that cells may be dying by apoptosis (see section 3.3.3. bellow). Indeed, even though no significant differences in the cell cycle profile were observed, there was a significant increase in the sub-G1 peak of the cells that had been treated with the GI 75 concentration of the extract, which is suggestive of cellular apoptosis. Nevertheless, this sub-G1 peak cannot be used as a conclusive marker of apoptosis (Kajstura et al., 2007) . In conclusion, these results suggest that one of the possible mechanisms of action of this phenolic extract is the induction of apoptosis.
L. vulpinum phenolic extract induced apoptosis in MCF-7 cells
Due to the above mentioned results (sections 3.3.1 and 3.3.2), the apoptotic levels of MCF-7 cells treated with the phenolic extract of L. vulpinum were studied, with the Annexin V-FITC/PI flow cytometry assay. The results obtained are presented in Table   3 .
The studied phenolic extract increased apoptosis in MCF-7 cells that had been treated for 48 h. In Blank and control cells the apoptosis levels were approximately 6 to 9%, which were within the normal values usually obtained for this cell line (Vaz et al., 2012b) . When cells were treated with the GI 50 concentration of the extract the percentage of cells undergoing apoptosis increased to 13.4% and when cells were treated with the GI 75 concentration of the extract the levels of apoptosis increased to 27%; in both cases, the increase was considered statistically significant (Table 3) .
Although flow cytometry is a very sensitive method, in order to corroborate the results obtained, a fluorescence microscopic examination of cells was performed. Cellular treatment with the studied phenolic extract caused formation of apoptotic bodies (marked with arrows), which is more visible with the GI 75 treatment (Fig. 4) . 6 ± 1 8.3 ± 0.6 9 ± 1 13.4 ± 0.8* 27 ± 4* Values correspond to the mean ± SE of three independent experiments. *Represents p < 0.05 when comparing the effect of the studied phenolic extract with the Blank cells. Therefore, it was confirmed that cellular treatment with this extract induced apoptosis.
In addition, the effect of the mushroom extract on the expression of some proteins involved in apoptosis was determined by Western blot (Fig. 5) . Results show that treatment of MCF-7 cells for 48 h with the GI 75 concentration of the extract caused a significant increase in the p53 tumour suppressor protein. This protein becomes activated in response to stress conditions and induces p21 expression, which acts as a regulator of the cell cycle at the G1 checkpoint (Tsujitani et al., 2012) . Accordingly, p21 levels were also found increased following cellular treatment with the GI 75 concentration of the extract.
Considering the verified increase in p53 levels and since p53 is a transcriptional factor which enhances the expression of genes involved in apoptosis such as Bax and PUMA, the cellular levels of Bax and PUMA were also evaluated (Charvet et al., 2011) . No alterations were observed in Bax and PUMA expression levels with either of the treatments (GI 50 and GI 75 ; Fig. 5A and 5B). Being regulated by p53, their expression levels would be expected to be enhanced; however, the results obtained may be justified by the fact that only the 48h time point was analysed or that other mechanisms of apoptosis induction are being induced. Therefore, the levels of Bcl-2 and Bcl-xL were also evaluated by Western Blot. The cellular levels of both protein levels were reduced following treatment with the extract (Fig. 5A) , and in the case of Bcl-xL this reduction was found to be statistically significant for both concentrations of the extract (GI 50 and GI 75 ; Fig. 5B ). The verified decrease in the Bcl-2 levels may be a cause or a consequence of the verified apoptosis. Indeed, apoptosis results in the activation of caspases which cause a series of cascade reactions that cleave essential proteins throughout the cell. Bcl-2 and Bcl-xL (anti-apoptotic proteins) may be cleaved by caspases, causing a reduction in their cellular levels and therefore further potentiating the apoptotic process (Fujita et al., 1998; Kirsch et al., 1999; Liang et al., 2002) . So, the verified decrease in Bcl-2 and Bcl-xL may be a cause and/or a consequence of the verified increase in apoptosis.
Caspase-9 is the initiator caspase, whose activation is required for subsequent downstream caspase activation (Wu, 2014) . Treatment of MCF-7 cells with the mushroom extract caused a decrease in procaspase-9 levels, suggesting that caspase-9 was activated. Usually, this decrease is accompanied by an appearance of a 37 kD cleavage product in the Western Blots (Sharma et al., 2012) ; however, we were not able to detect this band with the used antibody. Additionally, treatment with the GI 75 concentration of the phenolic extract significantly decreased total PARP levels ( Fig. 5A and 5B), which is also typical of the activation of the mitochondrial pathway of apoptosis (Huang et al., 2012) . 
L. vulpinum phenolic extract induced DNA damage
One of the causes of apoptotic cell death, namely via the intrinsic pathway, is DNA damage (Roos and Kaina, 2013) . Accordingly, it was decided to analyze the levels of p-H2A.X, a protein also related to DNA damage and repair. Although the results observed in the Fig. 5A (Western blot) seem to indicate an increase in p-H2A.X levels, we found that this increase was not statistically significant (Fig. 5B) .
In order to confirm if the mushroom extract induced DNA damage, the comet assay was performed. As aforementioned, cells were treated for 24 h with two different and high extract concentrations, 200 and 250 µg/mL (both higher than the GI 75 ), in order to see the induction of DNA damage before the reduction in the number of viable cells due to apoptosis occurred (which would mean that a very small number of cells would be analysed). By measuring the percentage of tail DNA obtained, a significant increase upon treatment with 250 µg/mL of the extract was observed (Fig. 6) . Therefore, it can be concluded that the phenolic extract from L. vulpinum causes effectively DNA damage. Overall, the phenolic extract from L. vulpinum seems to affect the human MCF-7 breast cancer cell line by causing DNA damage, which then probably caused a decrease in cellular proliferation and an increase in cell dead by apoptosis.
Indeed, the results obtained by flow cytometry (as well as fluorescence microscopy)
were conclusive and reported an increase in the percentage of MCF-7 cells undergoing programmed cell death following treatment with the studied phenolic extract. Moreover, it is well known that PARP is involved in the repair of DNA damage, being cleaved during apoptosis. In fact, cleavage of PARP by caspases is considered to be a hallmark of apoptosis (Chaitanya et al., 2010; Yang et al., 2004) . Therefore, our findings clearly suggest the induction of apoptosis by this extract. The decrease in procaspase-9 levels following treatment means that caspase-9 was activated. This protease is known to then activate the downstream caspases-3 and/or -7, which in turn cleave PARP (Ferguson et al., 2003) .
Additionally, even though the results obtained for p-H2AX have not been conclusive, the Comet assay proved that the extract induced DNA damage of MCF-7 cells.
Conclusions
This work was the first to report the bioactivity of L. vulpinum phenolic extract. This extract is characterised by the presence of hydroxybenzoic acids (gallic, protocatechuic and p-hydroxybenzoic acids) and the related compound cinnamic acid.
This mushroom extract seems to inhibit the growth of the human MCF-7 breast cancer cell line, by inducing DNA damage, inhibiting cellular proliferation and leading to cell death by apoptosis. This extract also revealed cytotoxic effects in the human breast nonmalignant cell line, but at much higher concentrations.
This work has provided further knowledge on the potential of L. vulpinum phenolic extract as a source of bioactive compounds with antitumour potential.
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